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High-grade osteosarcoma is an aggressive tumor most commonly aﬀecting adolescents. The early age of onset might suggest
genetic predisposition; however, the vast majority of the tumors are sporadic. Early onset, most often lack of a predisposing
condition or lesion, only infrequent (<2%) prevalence of inheritance, extensive genomic instability, and a wide histological
heterogeneity are just few factors to mention that make osteosarcoma diﬃcult to study. Therefore, it is sensible to design and
use models representative of the human disease. Here we summarize multiple osteosarcoma models established in vitro and in
vivo, comment on their utilities, and highlight newest achievements, such as the use of zebraﬁsh embryos. We conclude that
to gain a better understanding of osteosarcoma, simpliﬁcation of this extremely complex tumor is needed. Therefore, we parse
the osteosarcoma problem into parts and propose adequate models to study them each separately. A better understanding of
osteosarcoma provides opportunities for discovering and assaying novel eﬀective treatment strategies.
“Sometimes the model is more interesting than the original disease”
PJ Hoedemaeker (1937–2007).
1.Introduction
Osteosarcoma is a collective name for a broad spectrum of
osteogenic tumors [1, 2] of which the majority consists of
high-grade primary sarcomas referred to as “conventional
osteosarcoma.” Conventional osteosarcoma is characterized
byhighlocalaggressivenessandrapidmetastasizingpotential
resultinginanearlyonsettumor(meanageisabout17years)
[3] with poor survival—less than 60% after surgery and high
dose chemotherapy, less than 20% after relapse or chemore-
sistance, and less than 15% without chemotherapy [4–8].
Histologicallyawidespectrumofconventionalosteosarcoma
is found; however, without clear signiﬁcant diﬀerences of
clinical outcome related to the subtype [9]. The histological
heterogeneity of osteosarcoma might indicate a multipotent
cell of origin, which is most probably the mesenchymal stem
cell(MSC)alongitspathofdiﬀerentiationtotheosteoblastic
lineage [10–12]. A good comprehension of osteosarcoma
origin and etiology is complicated by several factors like its
extreme rearranged genome, the lack of precursor lesions
and the high genetic instability inhibiting the detection of
the driver genes. Furthermore, most osteosarcoma cases
occur sporadic—without obvious hereditary cause—with
an early onset resulting into a full-blown tumor at the
time of diagnosis. Moreover, although osteosarcoma is the
most common primary bone tumor and in the pediatric
age group it is the second highest cause of cancer-related
death, its overall prevalence is low (4-5 per 1.000.000, world
wide) [2], making it diﬃcult to study the disease in large
groups. Another limitation is caused by the administration
of presurgery high-dose chemotherapy, which has proven
its essence for patient’s survival but which, when eﬀective,
eradicates all cancer cells leaving barely any viable tissue in
the resected tumor to study.
For such a tumor with unknown origin, chaotic genetics,
early onset, and aggressive behavior, there is a need for
representative models providing possibilities to learn more
about the tumor biology in order to ﬁnd ways to target its
cancerous behavior. A similar conclusion was drawn a cen-
tury ago by Daels and Schurch who induced osteosarcoma2 Sarcoma
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Figure 1: Osteosarcoma models. Dendrogram shows reported osteosarcoma models divided into categories. References are provided for each
model.
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Figure 2: Animal cell lines. Schematic representation shows how
cell cultures are established from spontaneous canine or murine
osteosarcoma. After subsequent injections of the cells into mice,
tumorigenic and/or metastatic cultures can be established from the
tumors or the metastases, respectively. Please note that dissemina-
tion of cells after cell injections is often referred to as metastasis;
however, often it is not proved whether these cells are true
metastases from a primary tumor or cells that migrated through the
body after injection of the cell mass.
in experimental animals by exposing the bones to highly
radioactive materials [13–15]. Today an ideal osteosarcoma
model representing its biological, genetic and clinical fea-
turesunderpracticallabconditionsisstillmissing.Neverthe-
less, a number of human osteosarcoma cell lines have been
established and extensively characterized [16–18], sponta-
neous osteosarcoma is reported in mice [19–21] and is quite
common in dogs [22, 23], secondary osteosarcoma is found
in patients receiving radiation, patients of Paget’s disease of
bone and within syndromes like Li-Fraumeni and hereditary
retinoblastoma [2, 24], numerous syngeneic models have
beendeveloped,manyxenotransplantationstudieshavebeen
performed, and even in the latest years conditional mouse
osteosarcomamodelshavebeenestablished(Figure 1).Thus,
theoretically, there should be possibilities to uncover one
or more adequate osteosarcoma models for which we here
categorize models proposed in the literature and highlight
most recent ﬁndings towards modeling osteosarcoma.
2.In Vitro
2.1. Animal-Derived Cell Lines. The ﬁrst successfully estab-
lished metastatic osteosarcoma cell lines were derived from
spontaneous mouse osteosarcoma (Figure 2) including cell
lines K12 and K7M2 (developed from lung metastases of K7
cells in BALB/c mice) [13, 19, 25]. These lines were success-
fully proved to be metastatic and in later years used to assaySarcoma 3
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Figure 3:Humancelllinesandxenografts. Schematic representation
of how xenografts and cell cultures are established from human
osteosarcoma. After excision, the tumor is dissected into pieces of
which one ore more can be subcutaneously—or when technically
possible orthotopically—xenotransplanted into nude mice. Please
note that when dissemination is found in this situation, these
cells should be originating from the primary tumor and more
closely representing true metastasis. Subsequently, the process of
xenotransplantation can be repeated as often as needed to keep
the human tumor “alive” providing a source for research material.
Alternatively, after tumor excision, cell cultures can be established.
Subsequently, cells can be engineered—like the human osteosar-
coma cell line HOS—and injected into mice to assay the tumori-
genicity, metastatic potential, and other features. When established
xenografts and cell lines are shown to represent certain aspects of
human osteosarcoma, they can be used as models.
themetastaticprocessofosteosarcoma[26].Anothermurine
osteosarcoma cell line, the Dunn cell line, and its derivative
cell lines like LM8 were extensively used for screening new
osteosarcoma drugs and studying the inhibitory eﬀects of
these compounds on angiogenesis and metastasis [27–36].
In contrast to K12 and K7M2 cells, UMR 106-01 was not
aresultofspontaneousosteosarcomaasitisoriginatingfrom
a 32P-induced tumor in a rat [37]. However, because of its in
vitro and in vivo (in mouse tibia) exceptionally phenotypical
similaritiestohumanosteosarcoma,andtherapidformation
of pulmonary metastasis, this cell line has been studied at
length not only in osteosarcoma research [38] but also in
several other bone-related studies [38–41].
A number of cell lines have been derived from spon-
taneous canine osteosarcoma (Figure 2). In particular, D-
17 cell line originating from an osteosarcoma metastatic
to the lung in an 11-year-old female poodle [42]w a s
next to extensive use in viral studies, helpful for analyzing
immunotherapy of hepatic micrometastases [43]a sw e l la s
ﬁndingtherapeuticsforthetreatmentofbonecancerindogs.
2.2. Human-Derived Cell Lines. Starting with the establish-
ment of the ﬁrst human osteosarcoma cell line named U2OS
in 1964, many human osteosarcoma cell lines, such as HOS
and SAOS2, have been successfully established (Figure 3).
Despite comprehensive studies characterizing the U2OS cell
line in vitro [44–46], this cell line could not satisfy the need
for an in vivo metastatic model [47]. Unfortunately for all
subsequent human osteosarcoma cell lines this fact seemed
to be an important limitation. Only after characterization
of the HOS cell line [48] and production of its many
derivative cell lines after genetic alteration [49–53], the ﬁrst
in vivo tumorigenic and metastatic cell line, KRIB, later
named 143B, was generated [54]. Thereafter, many cell lines
were established, described in vitro and formed the basis
for studying numerous cellular processes either related to
cancer or not. Recently (epi)genetic, functional, and in vivo
characterizations of these cell lines were published to map
genetic [16] and epigenetic changes—by expression, methy-
lation, and micro-RNA proﬁling—diﬀerentiation capacity
and growth, invasion, and migration potential in nude mice
[17]. Based on these reports, together with a previous study
ofdrugresistanceinosteosarcomacelllines[55],appropriate
cell lines can be selected for the study of interest (Figure 4).
3.In Vivo
3.1. Cell Lines in Mice. Because of the high frequency of pri-
mary tumor development and frequent pulmonary metas-
tases when compared to human osteosarcoma cell lines
[13], most often murine osteosarcoma derived cell lines
have been inoculated into mice to establish in vivo models.
Despite the advantage that in these syngeneic models the
murine cells can grow in a murine microenvironment, these
models do not contain anything of human origin. For this,
human osteosarcoma cell lines have been engineered, like
HOS virally transformed to 143B and chemically to MNNG,
making them successfully tumorigenic and metastatic in vivo
and useful in animal models [56–59], keeping in mind that
a transformed cell line might not be a true representation of
thehumandisease.Nevertheless,thesemousemodelsproved
to be excellent models for identifying factors involved in
osteosarcoma migration and more importantly for screening
drugs to inhibit this [19, 25, 26, 60]. The limitation of such
models comes with the fact that studying fully developed
osteosarcoma cells does not provide constructive informa-
tion about the genesis of the tumor and its etiology. In
line with this, we recently showed that candidate progenitor
mesenchymal stem cells can be used to model osteosarcoma
origin and ﬁrst important events underlying its initiation
[61–63].
4. Xenotransplantation
An alternative to cell injections into recipient animals is to
transplant them with a piece of the tumor directly after
excision from the patient (Figure 3). In this way, the tumor
cells can grow in their own stroma, which is shown to be
essential for the tumor behavior [64, 65], and the cells do
not need to be cultured in vitro lowering the occurrence of
additional ex vivo changes. Moreover, reports suggest that
such xenotransplant models adequately represent the human
osteosarcoma characteristics [66, 67] (Kuijjer et al. BMC
Cancer, in press). Therefore, Professor Llombart-Bosch and
colleagues have xenotransplanted more than 500 sarcomas in
mice, kept the tumors “alive” for many years, and studied
them through many generations [68–71]. A drawback of this
system is that the implant inside the mouse rapidly will be4 Sarcoma
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Figure 4: Human osteosarcoma cell lines: which cell line to use? The ﬂow diagram suggests appropriate cell lines to use for certain research
question. Decision-making for this diagram is based on reported genetic, phenotypical and functional analyses of these cell lines, and lab
experience from unrelated experiments by the authors and direct collaborators.
inﬁltratedbymousecellspossiblyinﬂuencingtheactivitiesof
thetumorcellsandmoreimportantlyifthexenotransplantis
excised for cell culturing, the mouse cells can easily overgrow
the human cell population (unpublished data).
5.Radio-Carcinogen-Induced
Mouse Osteosarcoma
In the sixties, Finkel et al. assayed the inﬂuence and param-
eters of radiation on bone tumor development in mice [72].
By intravenous injections of the bone-seeking radionuclide
Ca45 in mice, a new osteosarcoma model was born. Although
to our knowledge, in the years after, the model has not
been reported in osteosarcoma research, recently Professor
Thomas and colleagues have reestablished the model (Fig-
ure 5). A drawback of the model is that—based on the
locations and the histology of the tumors—it most probably
and logically represents secondary osteosarcoma as seen in
postradiation osteosarcoma patients, which might not share
molecular mechanisms with primary osteosarcoma as most
often found in young patients with no history of radiation.
Nevertheless,as100%ofthefemalemicedeveloposteosarco-
Weekly low-dose i.p. injection of 
45Ca into 4 weeks old female mice 
for 4 weeks
8–12 months
100% osteosarcoma 
Figure 5: The radiocarcinogenic model. Schematic representation
of the radiocarcinogenic osteosarcoma mouse model showing
that 4-week old mice weekly receive low-dose injections of 45Ca
intraperitoneally (i.p.) for four weeks. Within 8–12 months, all
female mice develop osteosarcomas. Most lesions are located in the
spines of the animals, and metastases are not frequently found.
Please note that this ﬁgure is based on oral communication with
Professor Thomas.
mas within 8–12 months after treatment, the model provides
uniqueopportunitiestostudythiscancer.Moreover,afterthe
formation of the tumors, the model allows for subsequent
syngeneic transplantations in immune-competent mice to
study the host immune response.Sarcoma 5
6. CanineOsteosarcoma
Spontaneous osteosarcoma is less rare in large dogs than
in humans making the dog an attractive candidate model
to study the human disease [73]. Moreover, limited genetic
variation in inbred dogs allows for statistically acceptable
studies even with low number of cases [22]. Although os-
teosarcoma develops at later age in dogs, its biologic be-
havior and clinical representation is similar to that of hu-
man osteosarcoma [74]. Lately a new canine osteosarcoma
model was established in particular for the study of the
p53 pathway. In this paper, the authors propose that canine
p53 family proteins have biological activities comparable
to human equivalents making the dog an excellent out-
bred spontaneous osteosarcoma model. An idea shared by
researchers like Professor Kirpensteijn, who has studied
canine osteosarcoma for a long time [22, 74–77]. Despite
the availability of this relatively good representative model,
major breakthroughs still have not been made in osteosar-
coma understanding and treatment for the past 30 years,
which might be due to the very same sudden character
of the model. Having a spontaneous animal osteosarcoma
without any external manipulation and within its natural
environment might be the best option mirroring the human
situation, but simultaneously it might be as complicated
as human osteosarcoma to understand. One should realize
that the more representative a model becomes, resembling
the real human conditions, the more complicated it will
be to understand. The challenge is to ﬁnd a good balance
between the representativity and the controllability of a
model.
7. Paget’s Disease of Bone
Two important factors complicating osteosarcoma under-
standing are its low prevalence, which makes association and
linkagestudiesdiﬃcult,anditssuddenonset,whichobscures
possible premalignant events or lesions. One possibility to
come around these problems is to study a bone metabolic
disorder called the Paget’s disease of bone (PDB) or osteitis
deformans.Witha0.15–0.95%ofosteosarcomaprevalencein
PDB patients—a thousand fold higher chance as compared
tothenormalpopulation—PDBosteosarcomacouldbeused
for genetic studies to ﬁnd common variations in an uncom-
mon disease [78]. Moreover, as the PDB osteosarcoma is
secondary to an underlying predisposing condition, that is,
unbalanced bone metabolism, and as it occurs much later
in life [24, 79], it provides the opportunity to understand
molecular defects involved in osteosarcoma genesis. Accord-
ingly key players of the NF-κB pathway like the TNFRSF11A
gene could be studied in osteosarcoma. Unfortunately, ex-
a c t l yt h eo p p o s i t em i g h tb et r u ea sw e l ls i n c es e c o n d a r y
osteosarcoma might have a totally diverse biology compared
to primary osteosarcoma concordant with its diﬀerent clini-
cal features like the later age of onset and the location of the
tumors. This might explain why PDB osteosarcoma has not
often been used as a model to study osteosarcoma despite its
possible beneﬁts.
8. GeneticDisorders
Although genetic predisposition is only found in few osteo-
sarcoma cases, investigations in syndromes like Li-Fraumeni
(TP53), Retinoblastoma (RB1), and DNA helicase-related
conditions Rothmund-Thomson (RECQL4)a n dW e r n e r
(RECQL2) have led to speculation and identiﬁcation of some
of the most important genes involved in osteosarcoma, like
the RB1 gene mutations and TP53 germline mutations [80,
81]. A big pitfall in using these hereditary syndromes to
extract knowledge of osteosarcoma is that they are caused
by germline mutations in most important tumor suppressor
genes and/or oncogenes resulting in a broad spectrum of
malignancies of which osteosarcoma is only a small part.
Therefore,anyﬁndingfromthesesyndromerelatedosteosar-
coma models might be rather cancer-speciﬁc than osteosar-
coma speciﬁc.
9.Highlights
9.1. Conditional Mouse Model. Recently, Walkley et al.
developed an osteosarcoma conditional mouse model that
mimics human osteosarcoma phenotypically and genetically
farbetterthananymousemodelestablishedbefore[82].Pre-
viously a number of mouse strains were reported to develop
osteosarcoma upon genetic manipulations, like TP53 germ-
line mutation [83–85], osteoblast-restricted deletion of TP53
[86], overexpression of c-Fos [87–89], and heterozygous
mutation of Nf2 [90, 91]. However, the long latency of
osteosarcoma development combined with the low pen-
etrance and unspeciﬁc tumor development made them
impractical models. Making use of ﬂoxed conditional alleles
of both p53 and pRb genes, the Walkley model allows for
periodic and tissue-restricted inactivation of these genes
resulting into 100% speciﬁc and 100% penetrance osteosar-
coma development within three to ﬁve months. In line
with the human osteosarcoma, a substantial number of
the p53fl/fl-pRbfl/fl-osteosarcoma-bearing mice developed
metastases and high conservation of the genetical changes
betweenmouseandhumanosteosarcomawasdemonstrated.
Drawbacks of this osteosarcoma model include the incon-
sistency in tumor location since human osteosarcoma is
mostly located at the ends of the long bones, while in
Walkley mice the most frequent aﬀected sites were the jaw
and the head. Essential diﬀerences between endochondral
ossiﬁcation—formed from cartilage and mainly found in
long bones—and intramembranous ossiﬁcation—formed
from connective tissues like the mesenchyme and mainly
found in ﬂat bones—might be involved in this discrepancy.
More importantly, in this model most metastases were found
in the livers of the mice, again not representative of the
predominantlungmetastasesfoundinhumanosteosarcoma.
Interestingly in secondary osteosarcoma as, for example,
PDB osteosarcoma a similar pattern of tumor distribution
is more common. Furthermore, the loss of p53 and pRb
in this model might represent osteosarcoma in a genetic
predisposing condition parallel to the human situation in Li-
Fraumeni and Retinoblastoma patients. The other drawback
of the model is its assumption that osteosarcoma is derived6 Sarcoma
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Schematic representation of a transgenic zebraﬁsh embryo in which
all blood vessels are labeled in green. After injection of cells labeled
in red, the transparent embryos are screened daily to investigate
processes like intra/extravasation, migration (metastasis), and signs
of angiogenesis. In addition, by labeling immune cells with another
color (blue in this ﬁgure) or by examining the zebraﬁsh gene
expression proﬁles, the host response to the injected cells can be
studied.
from a late preosteoblastic stage (when osterix is expressed),
while it is not excluded that the transformation might even
happen before this stage [92]. Indeed this might explain the
narrow histological spectrum of these mice osteosarcoma
showing osteoblastic diﬀerentiation as compared to the
human osteosarcoma where many subtypes are found [1].
Recent reports show malignant transformation of normal
MSCs, which formed osteosarcoma lesions after this trans-
formation [62, 63, 92] providing evidence for an MSC origin
of osteosarcoma. Although technically more diﬃcult to hit
speciﬁcally and conditionally only mesenchymal stem cells,
inactivating p53 and pRb in these cells might result in a more
representative osteosarcoma model.
9.2. Zebraﬁsh Progression Model. In the most recent eﬀorts,
we have been working towards modeling other aspects of
osteosarcoma, which are its highly aggressive local growth
and its progression in terms of invasion, angiogenesis,
and metastasis. A better knowledge of these processes is
essentialfordesigningneweﬀectivetherapiessincethemajor
cause of mortality in osteosarcoma patients is metastasis
and not the primary tumor. As indicated, several mouse
models are available which could be used to assay these
processes; however, next to the above-mentioned drawbacks,
they are in general expensive and need a long period of
time for tumor initiation, tumor progression, and treat-
ment response. Therefore, a zebraﬁsh embryo model is
an attractive alternative in which within only 3 days after
tumor grafting, tumor cell homing, proliferation, migration,
and angiogenesis (Figure 6, Mohseny et al., manuscript
submitted) can be seen. As a proof of principal for the
validity of the model, we compared the behavior of the
previously published murine MSCs [62]b e f o r ea n da f t e r
transformation of the cells. Transgenic zebraﬁsh expressing
enhanced green ﬂuorescent protein (EGFP) in all blood
vessels [93] and transparent zebraﬁsh called Casper [94]
were crossed to produce transparent embryos with green
blood vessels in which cells with a red label were injected.
In contrast to the low passage MSCs, the transformed
MSCs showed—within 3 days after injection—excessive
proliferation, migration towards the body of the ﬁsh, and
angiogenesis. The advantages of this model as compared to
mouse models are its relatively low costs, its high statistical
power by the large group sizes, its high speed—most
experiments are done within 5 days—its reproducibility
and ease in dosing drugs since these are added into the
swimming water of the ﬁsh instead of adding to the food,
and its advantages in imaging by using transgenic ﬁsh. A
major drawback of the model is directly related to one of
its advantages, that is, the high speed. In its current form—
only three to ﬁve days of experiment and inside embryos—
there is no true tumor and stroma formation lacking a
representative microenvironment as compared to the human
situation. Nevertheless, with the many advantages and its
reported use in other cancers [93, 94], this model provides
new opportunities to be exploited in future osteosarcoma
studies.
10. Discussion
Theearlyonset,lackofapredisposingconditionorprecursor
lesion, and only infrequent (<2%) prevalence of inheritance
make osteosarcoma exceptional as compared to other malig-
nancies that result from a multistep genetic process over
many years like colorectal cancer. These factors together
withtheextensivegeneticinstabilityofosteosarcomahamper
the elucidation of the tumor’s biology [95]. Ideally, a
good osteosarcoma model should be able to recapitulate
crucial aspects of the human tumor, including osteoid pro-
duction, expression of biomarkers such as alkaline phos-
phatase (ALP), osteocalcin (OCN), and osteopontin (OP),
rapid tumour growth, local aggressiveness, pulmonary
metastases, and the genetic events underlying these processes
[59]. However, it is becoming increasingly more evident
that creating such a model for osteosarcoma is unrealistic
because of a chicken-and-egg situation—models are needed
to understand the complex etiology of the tumor while
understanding the etiology is needed to set up appropriate
models—and so on. To overcome this problem, instead of
trying to ﬁnd a single “perfect” osteosarcoma model, it is
more sensible to dissect this extremely complex tumor into
parts and to study them separately using adequate models.
In line with this, we distinguish four essential aspects in
osteosarcoma disease including the sudden rapid and early
onset, the high genomic instability, the local aggressiveness
and metastasis potential, and the need for targeted therapy.
For each of these aspects, there are now suitable models
available which could be utilized in the following Sections.
Challenges in the study of human conventional osteosar-
coma:
(i) early sudden onset,
(ii) infrequent prevalence,
(iii) no predisposing condition,
(iv) no precursor lesions,Sarcoma 7
(v) mainly sporadic,
(vi) extensive genomic instability,
(vii) many genetic alterations,
(viii) wide histological heterogeneity,
(ix) chemotherapy before surgery.
10.1. Genesis. To study the early steps in osteosarcoma-
genesis, the mouse mesenchymal stem cells (mMSCs) based
model—by which substantial evidence for a MSC origin of
osteosarcoma was provided [62, 63]—is useful. The clinical
validity of the model was conﬁrmed by the ﬁnding that
loss of CDKN2A/p16—one of the critical steps during
the malignant transformation of the MSCs—in human
osteosarcoma signiﬁcantly correlated with patients’ survival
[62]. Moreover, this loss was based on the same molecular
mechanism as in the model that is, genomic deletion [61].
For further knowledge of osteosarcoma-genesis, this model
provides the possibility to gradually analyze stages of os-
teosarcoma prior to the fully developed tumor. By com-
paring transformed MSCs to their normal parental MSCs—
preferentially by sequencing assays—driver mutations
underlying tumorigenic transformation can be identiﬁed as
all passenger mutations than would be excluded.
10.2. Etiology. As seen in clinical samples as well as in
human- or mouse-derived osteosarcoma cell lines, fully
developed osteosarcoma is characterized by a high degree of
genomic alterations and a continuous state of genomic insta-
bility. Although also the above-mentioned mMSC model
demonstrated genomic instability of the transformed MSCs
and despite the ongoing debate in the literature, solid reports
showing transformation of human MSCs to osteosarcoma
cells accompanied by genomic instability are still missing.
Nevertheless, this disturbance in the integrity of osteosar-
coma’s genome remains a crucial step in osteosarcoma-
genesis and might be studied in two steps. First, more insight
into mechanisms involved in genomic instability of mes-
enchymal cells is needed. A recently published mouse model
showing a crucial role of the Fzr1 gene in maintaining
genomic stability [96] provides opportunities to tackle this
problem. Bone-marrow-derived MSCs from Fzr1−/fl mice
could be studied to investigate the relation between genomic
instability and malignant transformation. Second, since
human MSCs do not seem to transform spontaneously,
genomic instability can be introduced to them by drugs like
nocodazole [97]. Hypothetically as a result of the genomic
instability, human MSCs will undergo apoptosis which
would require inactivation of the apoptotic pathway, that is,
deletion of the TP53 or the CDKN2A genes, to overcome
all the checkpoints and to allow the MSCs to proliferate
with abnormal genomes. These cells would provide essential
models for the early steps of osteosarcoma genesis.
10.3. Local Invasion and Dissemination. To study the aggres-
sive behavior and progression of osteosarcoma in a high
throughput manner, the recently established zebraﬁsh model
provides a better understanding of osteosarcoma cell inva-
sion, migration, and processes involving angiogenesis. The
advantages of this model as compared to mouse models are
its relatively low costs, its high statistical power and repro-
ducibility by the large group sizes, its short experimental
time span, its ease in dosing drugs since these are added
into the water the ﬁsh are swimming in instead of adding to
the food, and its advantages in imaging by using transgenic
ﬁsh. Hundreds of parameters can be screened, which would
allow for the selection of candidate genes involved in
migration and angiogenesis. Moreover, next to the cell
characteristics, the host (innate) immune response towards
the tumor cells can be monitored. A disadvantage of the
modelaccompaniedbytheshortdurationoftheexperiments
is the lack of tumor mass formation. Therefore, all selected
cell intrinsic candidate genes and immune-related response
genes can be further analyzed in the radiocarcinogenic
osteosarcoma mouse model. Currently, Professor Thomas is
studyingtheroleofabroadspectrumofimmunedeﬁciencies
and osteosarcoma formation and progression by using this
mouse model (presented at EuroBoNet annual meeting
2011).
10.4. Drug Screening. When the acquired basic understand-
ing by the ﬁrst two steps and the (pre-)screens by the third
step successfully identify clinically relevant candidate targets
to treat osteosarcoma, models are needed for drug screens.
As (pre-) screens again, the zebraﬁsh model provides an
eﬃcient manner to select candidate drugs. This time not
only tumor cell injections could be used, but also human
osteosarcoma-derived micro xenotransplants in the embryos
preserving the tumor micro environment. Subsequently, the
candidate drugs could be tested in mouse models. One
convenient model was identiﬁed by in vivo characterization
of 19 osteosarcoma cell lines showing that the HOS-143B
cell line—after subcutaneous injections into nude mice—
rapidly produced tumors which metastasized to the lungs.
Subsequently, the human osteosarcoma xenotransplanted
micecouldbeusedinwhichthetumorstromaismaintained.
Finally, when a model system is needed with an intact im-
mune system, the radiocarcinogenic osteosarcoma model
and spontaneous canine osteosarcoma models are most ap-
propriate.
Solutions to make the study of osteosarcoma possible are
presented. Multiplemodelscanbeusedtoinvestigateaspects
of osteosarcoma:
(i) initiation → mMSCs mouse model,
(ii) genomic instability →Fzr1 mouse model,
(iii) invasion, dissemination, and host response → ze-
braﬁsh cell injection and xenotransplantation mod-
els,
(iv) drug screening → Zebraﬁsh, (radiocarcinogenic)
mouse and canine models.
Conventional chemotherapy has been essential to im-
prove the survival of osteosarcoma patients up to 60–70%
but has reached a plateau phase. Attempts to invent more8 Sarcoma
eﬀective chemotherapeutic regimens have failed to further
improve survival [8]. Therefore, speciﬁc targets identiﬁed
and developed by comprehensive basic research and wide
screens of available drugs—the rarity of osteosarcoma ham-
pers development of new compounds by pharmaceutical
companies—are needed to precede clinical trials.
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